Navigation Links
Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
Date:1/30/2008

SAN CARLOS, Calif., Jan. 30 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it has enrolled the first patient in a single-center, Phase 1 trial to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172, a thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers.

"This proof-of-concept trial will allow us to quickly determine NU172's potential to achieve rapid onset and offset of anticoagulation," said Michael Levy, executive vice president of research and development for Nuvelo. "We look forward to sharing top-line data from this trial in the first half of 2008."

NU172 is an aptamer designed to directly inhibit thrombin's ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery and percutaneous interventions. Data from early animal models suggest that NU172 has the potential for predictable anticoagulant effects, rapid onset and offset of action, and avoidance of heparin-induced thrombocytopenia.

About Aptamers

Aptamers are chemically synthesized single-stranded nucleic acids that form well-defined three-dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Characteristics of aptamers include high specificity and affinity, and the ability to target protein-protein interactions.

About Nuvelo and Archemix's Joint Collaborative Effort

In August 2006, Nuvelo expanded its collaboration with Archemix to develop and commercialize aptamers that have a sho
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
2. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
3. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
4. Northwestern Memorial Transplant Program Initiates New Study
5. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
6. SGX Initiates Phase I Trials for SGX523
7. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
8. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
9. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
10. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
11. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, ... US Patent and Trademark Office (USPTO) has issued ... a dendritic cell-based immunotherapeutic vaccine targeting six tumor ... claims of US Patent No. 8,871,211, which issued ... cancer by administering a dendritic cell composition comprising ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014  RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced completion of enrollment in its ... from the 3-month observations confirmed the 1-month findings ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/17/2014)... Dec. 17, 2014 PCCA received the ... ( http://bit.ly/1382OkS ) program seal for best practices ... program highlights medical practices, materials and goods that ... Children affected by autism often have ... exacerbated by ingredients found in food and medicine ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
... WIRE)--Mar 7, 2007 - Gemin X,announced today ... version of,the journal Blood demonstrated that its ... against,patient-derived multiple myeloma tumor cells as a ... a combination therapy.,GX15-070 is a small molecule ...
... Placebo-controlled Study in Inoperable Chronic,Thromboembolic Pulmonary Hypertension ... Resistance Met - Six-Minute-walk,Test Unchanged - Significant ... , , ALLSCHWIL, Switzerland, March ... the initial results from the double-blind,placebo-controlled, multicenter ...
Cached Medicine Technology:Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood 2Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 2Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 4Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 5Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 6
(Date:12/15/2014)... 15, 2014 A recent survey found ... women as impacting skin health and beauty were: “Connections,” ... skin care.” Water and health advocate and radio host ... article describing the survey and the Four C’s.* Kleyne ... every category discussed would benefit from paying attention to ...
(Date:12/15/2014)... CARSON CITY, NV (PRWEB) December 15, 2014 ... new powerhouse company, JM Ocean Avenue. JM Ocean ... technology of the Veretekk online automated marketing system. ... by the June 2014 merger of Ocean Avenue and ... a more than $2 Billion per year company. , ...
(Date:12/15/2014)... December 15, 2014 South Florida’s leading urgent ... holidays can be a daze of hassle, hustle, and bustle ... while decking halls, to burns when making special meals and ... that can happen at any time. To prevent this season ... has made a list of helpful and healthful holiday tips ...
(Date:12/15/2014)... 2014 OutMarket , a provider ... Social Media Cheat Sheets ,” a guide that exposes ... results on the top ten social media networks. ... drive awareness, engagement, and customer service. It can also ... an impact on new networks and weather constantly changing ...
(Date:12/15/2014)... By Steven Reinberg ... -- A large, new study should reassure the millions of ... the risk for breast cancer. "There is no association ... Tamimi, an associate professor of medicine at Harvard Medical School. ... for concern, and there is no protective effect either." ...
Breaking Medicine News(10 mins):Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2
... , ... Shield of Texas has designated Houston Northwest Medical Center as a Blue Distinction Center for ... ... Northwest Medical Center as a Blue Distinction Center for Knee and Hip Replacement. Blue Distinction ...
... ... ... , ... , , ...
... ... ... , , , , ... ...
... , ... ... , , , ... Avon ...
... The National Institutes of Health has awarded a two-year ... the Bradley Hasbro Children,s Research Center to better understand ... disease (IBD), a condition that causes chronic and painful ... grant, funded by the American Recovery and Reinvestment Act ...
... and health care providers need to step up their ... pressure and better treat those with the condition, which ... half of heart failures in the United States each ... Medicine. Policies that create environments which ...
Cached Medicine News:Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement 3Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Knee and Hip Replacement 4Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 2Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 3Health News:Federal Government Premium Review Ignores Real Factors Driving Healthcare Costs 4Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 2Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 3Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 4Health News:AARP Makes Senate Vote on Idaho Health Freedom Act 'Accountability Vote' 5Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 2Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 3Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 4Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 5Health News:Survey Finds Access to Mammograms Declining for Women Under Age 50 6Health News:NIH grant will create behavioral health registry for pediatric inflammatory bowel disease 2Health News:NIH grant will create behavioral health registry for pediatric inflammatory bowel disease 3Health News:IOM report declares high blood pressure a neglected disease 2Health News:IOM report declares high blood pressure a neglected disease 3
... Intuition EMR Ophthalmology is a comprehensive ... tailored for ophthalmology practices. Intuition EMR ... but provides the tools to evaluate ... you to make better decisions and ...
... MaximEyes by First Insight is the ... records solution for eye care professionals. ... with Eyefinitys online servicesrequest VSP authorizations, ... MaximEyes offers EMR, scheduling, billing, demographics, ...
... latest in advanced cartridge mixing and delivery ... and mechanically injects all types of bone ... Revolution&trade line-up includes a large selection of ... in difficult to access areas. A new, ...
Simply stated, no bone cement can match the history of Simplex™. Simplex™ is the only cement with 40 years of proven clinical performance - trusted by tens of thousands of surgeons with o...
Medicine Products: